Second Generation Proteasome Inhibitor is More Potent than Doxorubicin (Firstline Drug) in Inhibiting Proliferation and Inducing Apoptosis in Human Triplenegative Breast MDAMB231 Cancer Cells
Volume: 227, Issue: 4, Pages: e7 - e7
Published: Oct 1, 2018
Abstract
Journal of the American College of Surgeons 227(4):p e7, October 2018. | DOI:...
Paper Details
Title
Second Generation Proteasome Inhibitor is More Potent than Doxorubicin (Firstline Drug) in Inhibiting Proliferation and Inducing Apoptosis in Human Triplenegative Breast MDAMB231 Cancer Cells
Published Date
Oct 1, 2018
Volume
227
Issue
4
Pages
e7 - e7
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History